Dimebon

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Huntington Disease

Conditions

Huntington Disease

Trial Timeline

Jul 1, 2009 → —

NCT ID

NCT00920946

About Dimebon

Dimebon is a phase 3 stage product being developed by Pfizer for Huntington Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00920946. Target conditions include Huntington Disease.

What happened to similar drugs?

1 of 10 similar drugs in Huntington Disease were approved

Approved (1) Terminated (2) Active (7)

✅TetrabenazineLundbeckApproved

🔄Votoplam (blinded) + PlaceboNovartisPhase 3

🔄RO7234292 (RG6042)RochePhase 3

🔄RO7234292 + PlaceboRochePhase 3

❌Dimebon (latrepirdine)PfizerPhase 3

🔄RiluzoleSanofiPhase 3

🔄ValbenazineNeurocrine BiosciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01152216	Phase 3	Terminated	Apr 1, 2010	—	Alzheimer's Disease
NCT00939783	Phase 3	Terminated	Sep 1, 2009	Aug 1, 2010	Alzheimer's Disease
NCT00920946	Phase 3	Completed	Jul 1, 2009	—	Huntington Disease

Competing Products

20 competing products in Huntington Disease

See all competitors

Product	Company	Stage	Hype Score
atomoxetine + Matching Placebo	Eli Lilly	Phase 2	35
Votoplam (blinded) + Placebo	Novartis	Phase 3	47
Votoplam	Novartis	Phase 2	39
Branaplam + Placebo	Novartis	Phase 2	27
AFQ056 + Placebo	Novartis	Phase 2	27
RO7234292 (RG6042)	Roche	Phase 1	29
Tominersen + Placebo	Roche	Phase 2	39
RO7234292 (RG6042)	Roche	Phase 3	40
RO7234292 (RG6042)	Roche	Phase 2	35
RG6496 + Placebo	Roche	Phase 1	36
RO7234292 + Placebo	Roche	Phase 3	40
PF-02545920 + PF-02545920	Pfizer	Phase 2	35
Dextromethorphan + Dimebon + Dextromethorphan	Pfizer	Phase 1	29
Dimebon (latrepirdine)	Pfizer	Phase 3	32
20 mg BID of PF-02545920	Pfizer	Phase 2	27
PF-02545920 + Placebo + PF-02545920 + Placebo	Pfizer	Phase 2	35
Riluzole	Sanofi	Phase 3	40
ALN-HTT02 + Placebo	Alnylam Pharmaceuticals	Phase 1	33
Tetrabenazine	Lundbeck	Approved	36
Valbenazine	Neurocrine Biosciences	Phase 3	41